Review



8 × 15 k human microrna-specific microarray v2 platform  (Agilent technologies)


Bioz Verified Symbol Agilent technologies is a verified supplier
Bioz Manufacturer Symbol Agilent technologies manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Agilent technologies 8 × 15 k human microrna-specific microarray v2 platform
    MicroRNAs that separate tumour from normal . The intersection of three separate statistical tests yielded 127 <t>microRNA</t> that more significantly differentiate tumour from normal samples. The tests included an unpaired T-test ( p < 0.05) with a Benjamini Hochberg FDR multiple testing correction and an unpaired Mann-Whitney test ( p < 0.05) with a Benjamini Hochberg FDR multiple testing correction from within GeneSpring GX 11.0, and a Student's t-test ( p < 0.05). Data for these 127 microRNA were subsequently used for further clustering of the samples and SNR analysis to uncover the top microRNA which differentiate tumour and normal samples.
    8 × 15 K Human Microrna Specific Microarray V2 Platform, supplied by Agilent technologies, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/8+%C3%97+15+k+human+microrna-specific+microarray+v2+platform/pmc03342161-75-43-38
    Average 90 stars, based on 1 article reviews
    8 × 15 k human microrna-specific microarray v2 platform - by Bioz Stars, 2026-10
    90/100 stars

    Images

    1) Product Images from "Identifying microRNA/mRNA dysregulations in ovarian cancer"

    Article Title: Identifying microRNA/mRNA dysregulations in ovarian cancer

    Journal: BMC Research Notes

    doi: 10.1186/1756-0500-5-164

    MicroRNAs that separate tumour from normal . The intersection of three separate statistical tests yielded 127 microRNA that more significantly differentiate tumour from normal samples. The tests included an unpaired T-test ( p < 0.05) with a Benjamini Hochberg FDR multiple testing correction and an unpaired Mann-Whitney test ( p < 0.05) with a Benjamini Hochberg FDR multiple testing correction from within GeneSpring GX 11.0, and a Student's t-test ( p < 0.05). Data for these 127 microRNA were subsequently used for further clustering of the samples and SNR analysis to uncover the top microRNA which differentiate tumour and normal samples.
    Figure Legend Snippet: MicroRNAs that separate tumour from normal . The intersection of three separate statistical tests yielded 127 microRNA that more significantly differentiate tumour from normal samples. The tests included an unpaired T-test ( p < 0.05) with a Benjamini Hochberg FDR multiple testing correction and an unpaired Mann-Whitney test ( p < 0.05) with a Benjamini Hochberg FDR multiple testing correction from within GeneSpring GX 11.0, and a Student's t-test ( p < 0.05). Data for these 127 microRNA were subsequently used for further clustering of the samples and SNR analysis to uncover the top microRNA which differentiate tumour and normal samples.

    Techniques Used: MANN-WHITNEY

    PCA on robust microRNA data reveals distinct separation . PCA was executed using only the expression data from the 127 microRNA represented in Figure 1. A clear separation between tumour and normal samples validates the effectiveness of the methods used to generate this microRNA list.
    Figure Legend Snippet: PCA on robust microRNA data reveals distinct separation . PCA was executed using only the expression data from the 127 microRNA represented in Figure 1. A clear separation between tumour and normal samples validates the effectiveness of the methods used to generate this microRNA list.

    Techniques Used: Expressing

    A separate cluster for normal samples implies significance of 18 microRNA . We K-means clustered (k = 3) all samples using microRNA expression data exclusively from the 18 microRNA in Table 1. The results are consistent with our expectation that these 18 microRNA best separate the cancerous samples from normal ovarian tissue.
    Figure Legend Snippet: A separate cluster for normal samples implies significance of 18 microRNA . We K-means clustered (k = 3) all samples using microRNA expression data exclusively from the 18 microRNA in Table 1. The results are consistent with our expectation that these 18 microRNA best separate the cancerous samples from normal ovarian tissue.

    Techniques Used: Expressing

    Anti-correlated and positively correlated mRNA/microRNA pairs in the tumour and/or the normal samples
    Figure Legend Snippet: Anti-correlated and positively correlated mRNA/microRNA pairs in the tumour and/or the normal samples

    Techniques Used:

    Anti-correlated and positively correlated mRNA/microRNA pairs in the tumour and/or the normal samples
    Figure Legend Snippet: Anti-correlated and positively correlated mRNA/microRNA pairs in the tumour and/or the normal samples

    Techniques Used:

    Related Articles

    Microarray:

    Article Title: Identifying microRNA/mRNA dysregulations in ovarian cancer
    Article Snippet: These data were obtained from the Data Access Matrix within the TCGA data portal ( http://cancergenome.nih.gov/dataportal/data/access/ ). cDNA microarray experiments measuring mRNA expression were run on the Affymetrix HG-U133A platform (22,277 probesets). microRNA experiments were performed on the Agilent 8 × 15 K Human microRNA-specific microarray V2 platform measuring the expression of 821 microRNAs.

    Article Title: An integrated model of clinical information and gene expression for prediction of survival in ovarian cancer patients.
    Article Snippet: Accepted Manuscript An Integrated Model of Clinical Information and Gene Expression for Prediction of Survival in Ovarian Cancer Patients Rendong Yang, Jie Xiong, Defeng Deng, Yiren Wang, Hequn Liu, Guli Jiang, Yangqin Peng, Xiaoning Peng, Xiaomin Zeng PII: S1931-5244(16)00070-0 DOI: 10.1016/j.trsl.2016.03.001 Reference: TRSL 1021 To appear in: Translational Research Received Date: 15 September 2015 Revised Date: 1 March 2016 Accepted Date: 2 March 2016 Please cite this article as: Yang R, Xiong J, Deng D, Wang Y, Liu H, Jiang G, Peng Y, Peng X, Zeng X, An Integrated Model of Clinical Information and Gene Expression for Prediction of Survival in Ovarian Cancer Patients, Translational Research (2016), doi: 10.1016/j.trsl.2016.03.001.. This is a PDF file of an unedited manuscript that has been accepted for publication.. As a service to our customers we are providing this early version of the manuscript.

    Article Title: Expression profiles analysis reveals an integrated miRNA-lncRNA signature to predict survival in ovarian cancer patients with wild-type BRCA1/2
    Article Snippet: The level 3 miRNA expression profile based on the Agilent 8 × 15 K Human microRNA-specific microarray V2 platform was obtained from TCGA data portal.

    Expressing:

    Article Title: Identifying microRNA/mRNA dysregulations in ovarian cancer
    Article Snippet: These data were obtained from the Data Access Matrix within the TCGA data portal ( http://cancergenome.nih.gov/dataportal/data/access/ ). cDNA microarray experiments measuring mRNA expression were run on the Affymetrix HG-U133A platform (22,277 probesets). microRNA experiments were performed on the Agilent 8 × 15 K Human microRNA-specific microarray V2 platform measuring the expression of 821 microRNAs.

    Article Title: An integrated model of clinical information and gene expression for prediction of survival in ovarian cancer patients.
    Article Snippet: Accepted Manuscript An Integrated Model of Clinical Information and Gene Expression for Prediction of Survival in Ovarian Cancer Patients Rendong Yang, Jie Xiong, Defeng Deng, Yiren Wang, Hequn Liu, Guli Jiang, Yangqin Peng, Xiaoning Peng, Xiaomin Zeng PII: S1931-5244(16)00070-0 DOI: 10.1016/j.trsl.2016.03.001 Reference: TRSL 1021 To appear in: Translational Research Received Date: 15 September 2015 Revised Date: 1 March 2016 Accepted Date: 2 March 2016 Please cite this article as: Yang R, Xiong J, Deng D, Wang Y, Liu H, Jiang G, Peng Y, Peng X, Zeng X, An Integrated Model of Clinical Information and Gene Expression for Prediction of Survival in Ovarian Cancer Patients, Translational Research (2016), doi: 10.1016/j.trsl.2016.03.001.. This is a PDF file of an unedited manuscript that has been accepted for publication.. As a service to our customers we are providing this early version of the manuscript.

    Article Title: Expression profiles analysis reveals an integrated miRNA-lncRNA signature to predict survival in ovarian cancer patients with wild-type BRCA1/2
    Article Snippet: The level 3 miRNA expression profile based on the Agilent 8 × 15 K Human microRNA-specific microarray V2 platform was obtained from TCGA data portal.

    MANN-WHITNEY:

    Article Title: Identifying microRNA/mRNA dysregulations in ovarian cancer
    Article Snippet: These data were obtained from the Data Access Matrix within the TCGA data portal ( http://cancergenome.nih.gov/dataportal/data/access/ ). cDNA microarray experiments measuring mRNA expression were run on the Affymetrix HG-U133A platform (22,277 probesets). microRNA experiments were performed on the Agilent 8 × 15 K Human microRNA-specific microarray V2 platform measuring the expression of 821 microRNAs.

    Article Title: An integrated model of clinical information and gene expression for prediction of survival in ovarian cancer patients.
    Article Snippet: Accepted Manuscript An Integrated Model of Clinical Information and Gene Expression for Prediction of Survival in Ovarian Cancer Patients Rendong Yang, Jie Xiong, Defeng Deng, Yiren Wang, Hequn Liu, Guli Jiang, Yangqin Peng, Xiaoning Peng, Xiaomin Zeng PII: S1931-5244(16)00070-0 DOI: 10.1016/j.trsl.2016.03.001 Reference: TRSL 1021 To appear in: Translational Research Received Date: 15 September 2015 Revised Date: 1 March 2016 Accepted Date: 2 March 2016 Please cite this article as: Yang R, Xiong J, Deng D, Wang Y, Liu H, Jiang G, Peng Y, Peng X, Zeng X, An Integrated Model of Clinical Information and Gene Expression for Prediction of Survival in Ovarian Cancer Patients, Translational Research (2016), doi: 10.1016/j.trsl.2016.03.001.. This is a PDF file of an unedited manuscript that has been accepted for publication.. As a service to our customers we are providing this early version of the manuscript.

    Article Title: Expression profiles analysis reveals an integrated miRNA-lncRNA signature to predict survival in ovarian cancer patients with wild-type BRCA1/2
    Article Snippet: The level 3 miRNA expression profile based on the Agilent 8 × 15 K Human microRNA-specific microarray V2 platform was obtained from TCGA data portal.



    Similar Products

    8 × 15 k human microrna-specific microarray v2 platform  (Agilent technologies)
    90
    Agilent technologies 8 × 15 k human microrna-specific microarray v2 platform
    MicroRNAs that separate tumour from normal . The intersection of three separate statistical tests yielded 127 <t>microRNA</t> that more significantly differentiate tumour from normal samples. The tests included an unpaired T-test ( p < 0.05) with a Benjamini Hochberg FDR multiple testing correction and an unpaired Mann-Whitney test ( p < 0.05) with a Benjamini Hochberg FDR multiple testing correction from within GeneSpring GX 11.0, and a Student's t-test ( p < 0.05). Data for these 127 microRNA were subsequently used for further clustering of the samples and SNR analysis to uncover the top microRNA which differentiate tumour and normal samples.
    8 × 15 K Human Microrna Specific Microarray V2 Platform, supplied by Agilent technologies, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/8+%C3%97+15+k+human+microrna-specific+microarray+v2+platform/pmc03342161-75-43-38
    Average 90 stars, based on 1 article reviews
    8 × 15 k human microrna-specific microarray v2 platform - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    MicroRNAs that separate tumour from normal . The intersection of three separate statistical tests yielded 127 microRNA that more significantly differentiate tumour from normal samples. The tests included an unpaired T-test ( p < 0.05) with a Benjamini Hochberg FDR multiple testing correction and an unpaired Mann-Whitney test ( p < 0.05) with a Benjamini Hochberg FDR multiple testing correction from within GeneSpring GX 11.0, and a Student's t-test ( p < 0.05). Data for these 127 microRNA were subsequently used for further clustering of the samples and SNR analysis to uncover the top microRNA which differentiate tumour and normal samples.

    Journal: BMC Research Notes

    Article Title: Identifying microRNA/mRNA dysregulations in ovarian cancer

    doi: 10.1186/1756-0500-5-164

    Figure Lengend Snippet: MicroRNAs that separate tumour from normal . The intersection of three separate statistical tests yielded 127 microRNA that more significantly differentiate tumour from normal samples. The tests included an unpaired T-test ( p < 0.05) with a Benjamini Hochberg FDR multiple testing correction and an unpaired Mann-Whitney test ( p < 0.05) with a Benjamini Hochberg FDR multiple testing correction from within GeneSpring GX 11.0, and a Student's t-test ( p < 0.05). Data for these 127 microRNA were subsequently used for further clustering of the samples and SNR analysis to uncover the top microRNA which differentiate tumour and normal samples.

    Article Snippet: These data were obtained from the Data Access Matrix within the TCGA data portal ( http://cancergenome.nih.gov/dataportal/data/access/ ). cDNA microarray experiments measuring mRNA expression were run on the Affymetrix HG-U133A platform (22,277 probesets). microRNA experiments were performed on the Agilent 8 × 15 K Human microRNA-specific microarray V2 platform measuring the expression of 821 microRNAs.

    Techniques: MANN-WHITNEY

    PCA on robust microRNA data reveals distinct separation . PCA was executed using only the expression data from the 127 microRNA represented in Figure 1. A clear separation between tumour and normal samples validates the effectiveness of the methods used to generate this microRNA list.

    Journal: BMC Research Notes

    Article Title: Identifying microRNA/mRNA dysregulations in ovarian cancer

    doi: 10.1186/1756-0500-5-164

    Figure Lengend Snippet: PCA on robust microRNA data reveals distinct separation . PCA was executed using only the expression data from the 127 microRNA represented in Figure 1. A clear separation between tumour and normal samples validates the effectiveness of the methods used to generate this microRNA list.

    Article Snippet: These data were obtained from the Data Access Matrix within the TCGA data portal ( http://cancergenome.nih.gov/dataportal/data/access/ ). cDNA microarray experiments measuring mRNA expression were run on the Affymetrix HG-U133A platform (22,277 probesets). microRNA experiments were performed on the Agilent 8 × 15 K Human microRNA-specific microarray V2 platform measuring the expression of 821 microRNAs.

    Techniques: Expressing

    A separate cluster for normal samples implies significance of 18 microRNA . We K-means clustered (k = 3) all samples using microRNA expression data exclusively from the 18 microRNA in Table 1. The results are consistent with our expectation that these 18 microRNA best separate the cancerous samples from normal ovarian tissue.

    Journal: BMC Research Notes

    Article Title: Identifying microRNA/mRNA dysregulations in ovarian cancer

    doi: 10.1186/1756-0500-5-164

    Figure Lengend Snippet: A separate cluster for normal samples implies significance of 18 microRNA . We K-means clustered (k = 3) all samples using microRNA expression data exclusively from the 18 microRNA in Table 1. The results are consistent with our expectation that these 18 microRNA best separate the cancerous samples from normal ovarian tissue.

    Article Snippet: These data were obtained from the Data Access Matrix within the TCGA data portal ( http://cancergenome.nih.gov/dataportal/data/access/ ). cDNA microarray experiments measuring mRNA expression were run on the Affymetrix HG-U133A platform (22,277 probesets). microRNA experiments were performed on the Agilent 8 × 15 K Human microRNA-specific microarray V2 platform measuring the expression of 821 microRNAs.

    Techniques: Expressing

    Anti-correlated and positively correlated mRNA/microRNA pairs in the tumour and/or the normal samples

    Journal: BMC Research Notes

    Article Title: Identifying microRNA/mRNA dysregulations in ovarian cancer

    doi: 10.1186/1756-0500-5-164

    Figure Lengend Snippet: Anti-correlated and positively correlated mRNA/microRNA pairs in the tumour and/or the normal samples

    Article Snippet: These data were obtained from the Data Access Matrix within the TCGA data portal ( http://cancergenome.nih.gov/dataportal/data/access/ ). cDNA microarray experiments measuring mRNA expression were run on the Affymetrix HG-U133A platform (22,277 probesets). microRNA experiments were performed on the Agilent 8 × 15 K Human microRNA-specific microarray V2 platform measuring the expression of 821 microRNAs.

    Techniques:

    Anti-correlated and positively correlated mRNA/microRNA pairs in the tumour and/or the normal samples

    Journal: BMC Research Notes

    Article Title: Identifying microRNA/mRNA dysregulations in ovarian cancer

    doi: 10.1186/1756-0500-5-164

    Figure Lengend Snippet: Anti-correlated and positively correlated mRNA/microRNA pairs in the tumour and/or the normal samples

    Article Snippet: These data were obtained from the Data Access Matrix within the TCGA data portal ( http://cancergenome.nih.gov/dataportal/data/access/ ). cDNA microarray experiments measuring mRNA expression were run on the Affymetrix HG-U133A platform (22,277 probesets). microRNA experiments were performed on the Agilent 8 × 15 K Human microRNA-specific microarray V2 platform measuring the expression of 821 microRNAs.

    Techniques: